Braveheart Bio, Inc. Common Stock (BRVE) Stock
Key stats
- Market cap
- $1.88B
- Price / Earnings ratio
- -26.7x
- EPS (TTM)
- -$3.93
- Volume
- Loading
- 52-week high
- $32.00
- 52-week low
- $16.70
Source: third-party data provider, as of November 13, 2026
Compare with BRVE
Recent news

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
BRVE

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
BRVE

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
BRVE
Technical indicators
- RSI 14
- 50.41
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- -0.65
- MACD histogram
- 0.06
- SMA 50
- $22.34
- Price below SMA 50
- EMA 50
- $22.53
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
BRVE

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
BRVE

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
BRVE
About Braveheart Bio, Inc. Common Stock
Braveheart Bio is a clinical-stage biopharmaceutical developer focused on therapies for patients with hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor ("CMI") being developed for the treatment of obstructive HCM ("oHCM") and non-obstructive HCM ("nHCM").
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Travis Murdoch B.S., M.D., M.Sc. | CEO, President & Director | 1985 |
| Mr. James Paul Rickey CPA | Chief Financial Officer | 1979 |
| Ms. Michele A. Anderson | Chief Development Officer | 1967 |
| Mr. Marc Evanchik M.S. | Chief Scientific Officer | 1973 |
| Ms. Natalie Dement J.D. | VP & Head of Legal | — |
| Mr. Timothy Y. Zhou | Director of Corporate Development | — |
| Ms. Steph Palencia | Associate Director of Human Resources & Office Manager | — |
| Ms. Brittany de Temple | Senior Vice President of Development Operations | — |
| Dr. Emil M. deGoma M.D. | Chief Medical Officer | 1976 |
| Mr. Tyler Chavez Ph.D. | Chief Business Officer | 1989 |
Fundamentals
Valuation
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.41
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- -0.65
- MACD histogram
- 0.06
- SMA 50
- $22.34
- Price below SMA 50
- EMA 50
- $22.53
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $44.33
- High
- $48.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.4 | -23.1 | +0.5 | -0.7 |



